Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Ghezzi

Showing results (141-150 of 149) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 149 results.
Nature Medicine|April 17, 2007
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitmentJürgen Bernhagen, Regina Krohn, Hongqi Lue, et al.
Pharmacological Reviews|August 30, 2020
On the Clinical Pharmacology of Reactive Oxygen SpeciesAna I Casas, Cristian Nogales, Hermann A M Mucke, et al.
Antioxidants & Redox Signaling|September 29, 2015
Clinical Relevance of Biomarkers of Oxidative StressJeroen Frijhoff, Paul G Winyard, Neven Zarkovic, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2003
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivoSerhat Erbayraktar, Giovanni Grasso, Alessandra Sfacteria, et al.
Science (New York, N.Y.)|July 13, 2004
Derivatives of erythropoietin that are tissue protective but not erythropoieticMarcel Leist, Pietro Ghezzi, Giovanni Grasso, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2004
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injuryRiccardo Bertini, Marcello Allegretti, Cinzia Bizzarri, et al.
Nature Immunology|October 21, 2010
IL-1 family nomenclatureCharles Dinarello, William Arend, John Sims, et al.
Lancet (London, England)|July 9, 2010
Erythropoietin: not just about erythropoiesisPietro Ghezzi, Myrian Bernaudin, Myriam Bernaudinb, et al.
Redox Biology|June 4, 2017
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)Javier Egea, Isabel Fabregat, Yves M Frapart, et al.
Pageof 15

Showing results (141-150 of 149) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 149 results.
Nature Medicine|April 17, 2007
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitmentJürgen Bernhagen, Regina Krohn, Hongqi Lue, et al.
Pharmacological Reviews|August 30, 2020
On the Clinical Pharmacology of Reactive Oxygen SpeciesAna I Casas, Cristian Nogales, Hermann A M Mucke, et al.
Antioxidants & Redox Signaling|September 29, 2015
Clinical Relevance of Biomarkers of Oxidative StressJeroen Frijhoff, Paul G Winyard, Neven Zarkovic, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 15, 2003
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivoSerhat Erbayraktar, Giovanni Grasso, Alessandra Sfacteria, et al.
Science (New York, N.Y.)|July 13, 2004
Derivatives of erythropoietin that are tissue protective but not erythropoieticMarcel Leist, Pietro Ghezzi, Giovanni Grasso, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2004
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injuryRiccardo Bertini, Marcello Allegretti, Cinzia Bizzarri, et al.
Nature Immunology|October 21, 2010
IL-1 family nomenclatureCharles Dinarello, William Arend, John Sims, et al.
Lancet (London, England)|July 9, 2010
Erythropoietin: not just about erythropoiesisPietro Ghezzi, Myrian Bernaudin, Myriam Bernaudinb, et al.
Redox Biology|June 4, 2017
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)Javier Egea, Isabel Fabregat, Yves M Frapart, et al.
Pageof 15